

Svetlana V Villevalde

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1269835/publications.pdf>

Version: 2024-02-01

47
papers

3,135
citations

759055

12
h-index

223716

46
g-index

59
all docs

59
docs citations

59
times ranked

3421
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure. Russian Journal of Cardiology, 2022, 26, 4800.	0.4	2
2	Frequency of hemodynamic response to orthostatic stress in heart failure with reduced ejection fraction, associations with clinical blood pressure. Russian Journal of Cardiology, 2022, 27, 5005.	0.4	1
3	An open-label multicenter observational study (registry) of patients recovered from coronavirus disease 2019 (COVID-19) with involvement of the cardiovascular system or with baseline severe cardiovascular diseases: rationale, design, and implications for clinical practice. Russian Journal of Cardiology, 2021, 26, 4287.	0.4	13
4	Antithrombotic therapy in the elderly and senile age: the consensus opinion of experts of the Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2847.	0.4	3
5	Arterial hypertension and antihypertensive therapy in older patients. The agreed opinion of experts from the Russian Association of Gerontologists and Geriatricians, the Antihypertensive League, the National Society for Preventive Cardiology. Rational Pharmacotherapy in Cardiology, 2021, 17, 642-661.	0.3	4
6	Types of hemodynamic response to orthostasis according to continuous blood pressure monitoring: a case series of heart failure with reduced ejection fraction. Russian Journal of Cardiology, 2021, 26, 4574.	0.4	0
7	Principles of organization of medical care for patients with heart failure in the system of cardiovascular risk management: focus on continuity of care and patient routing. Practical materials. Russian Journal of Cardiology, 2021, 26, 4558.	0.4	8
8	ICD-10 code-based definition of heart failure in Saint Petersburg electronic health records: prevalence, health care utilization and outcomes. Russian Journal of Cardiology, 2021, 26, 4621.	0.4	4
9	Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial. Terapevticheskii Arkhiv, 2021, 93, 1491-1497.	0.2	6
10	Rationale and design of multicenter prospective observational study of types, GRAde, Variability, associations and prognosis of orthostatic responses in Heart Failure (GRAVITY-HF). Russian Journal of Cardiology, 2020, 25, 78-82.	0.4	3
11	Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology, 2020, 25, 3786.	0.4	309
12	Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology, 2020, 25, 3801.	0.4	74
13	Implemented models and elements for heart failure care in the regions of the Russian Federation: prospects for transformation into regional cardiovascular risk management systems. Russian Journal of Cardiology, 2020, 25, 3792.	0.4	14
14	Assessment of prevalence and monitoring of outcomes in patients with heart failure in Russia. Russian Journal of Cardiology, 2020, 25, 4204.	0.4	7
15	Ventricular-arterial coupling parameters and its prognostic value in patients with decompensated heart failure. Russian Journal of Cardiology, 2020, 25, 39-45.	0.4	0
16	Clinical performance of the atrial fibrillation in the Russian population depending on the antithrombotic therapy: findings from the GLORIA-AF registry phase 2. Russian Journal of Cardiology, 2020, 25, 4179.	0.4	1
17	Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases. Russian Journal of Cardiology, 2020, 25, 4142.	0.4	3
18	Relationship of Liver Stiffness With Congestion in Patients Presenting With Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2019, 25, 176-187.	0.7	29

#	ARTICLE	IF	CITATIONS
19	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 121-130.	6.3	1,625
20	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 131-138.	6.3	394
21	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019, 393, 1937-1947.	6.3	408
22	Cardiovascular risk management system: prerequisites for developing, organization principles, target groups. <i>Russian Journal of Cardiology</i> , 2019, , 69-82.	0.4	44
23	Comparative analysis of antihypertensive effects of chlorthalidone and indapamide-retard in combination with azilsartan medoxomil in patients with arterial hypertension. <i>Russian Journal of Cardiology</i> , 2019, , 122-130.	0.4	3
24	Abnormal phenotypes of 24-h blood pressure monitoring and their associations with inflammation and arterial stiffness in patients with rheumatoid arthritis. <i>Arterial Hypertension (Russian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 537 Td (</i>		
25	EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 210-216.	0.3	2
26	NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 298-305.	0.3	0
27	Russian Society of Cardiology position paper on 2018 Guidelines of the European Society of Cardiology/European Society of Arterial Hypertension for the management of arterial hypertension. <i>Russian Journal of Cardiology</i> , 2018, , 131-142.	0.4	35
28	Deficit of Magnesium and States of Hypercoagulation: Intellectual Analysis of Data Obtained From a Sample of Patients Aged 18â€“50 years From Medical and Preventive Facilities in Russia. <i>Kardiologiya</i> , 2018, 17, 22-35.	0.3	11
29	Prognostic value of liver stiffness in decompensated heart failure: results of prospective observational transient elastography-based study. <i>Kardiologiya</i> , 2018, 17, 20-32.	0.3	9
30	Characteristics and clinical associations of arterial stiffness and subclinical atherosclerosis in patients with rheumatoid arthritis. <i>Kardiologiya</i> , 2018, 17, 46-54.	0.3	3
31	Experience of hospital initiation of sacubitril/valsartan in a female patient after acute decompensated heart failure. <i>Kardiologiya</i> , 2018, 17, 60-64.	0.3	0
32	Problems of anticoagulation therapy in patients with chronic heart failure and atrial fibrillation: role of rivaroxaban. <i>Kardiologiya</i> , 2018, 17, 33-41.	0.3	1
33	THE PREVALENCE OF CHRONIC KIDNEY DISEASE MARKERS IN ARTERIAL HYPERTENSION PATIENTS AND RELATION WITH DIABETES: RESULTS OF EPIDEMIOLOGICAL STUDY KHRONOGRAPH. <i>Russian Journal of Cardiology</i> , 2018, , 91-101.	0.4	5
34	EFFECT OF SACUBITRIL/VALSARTAN ON NATRIURESIS, DIURESIS AND BLOOD PRESSURE IN HYPERTENSIVE PATIENTS. <i>Rational Pharmacotherapy in Cardiology</i> , 2017, 13, 370-377.	0.3	1
35	GENETIC PREDICTORS OF INTENSIVE LIPID-LOWERING THERAPY EFFICACY AND ITS ANTI-INFLAMMATORY EFFECTS IN VERY HIGH CARDIOVASCULAR RISK PATIENTS. <i>Rational Pharmacotherapy in Cardiology</i> , 2017, 13, 525-531.	0.3	0
36	ARTERIAL HYPERTENSION MANAGEMENT IN PATIENTS AGED OLDER THAN 80 YEARS AND PATIENTS WITH THE SENILE ASTHENIA. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2017, 16, 8-21.	0.4	9

#	ARTICLE	IF	CITATIONS
37	CARDIORENAL INTERACTION IN DECOMPENSATED CHRONIC HEART FAILURE. Rational Pharmacotherapy in Cardiology, 2016, 12, 138-146.	0.3	8
38	Organoprotective effects of serelaxin in patients with severe decompensated heart failure. Rational Pharmacotherapy in Cardiology, 2016, 12, 414-423.	0.3	0
39	SP219PROGNOSTIC VALUE OF BIOIMPEDANCE VECTOR ANALYSIS VERSUS CLINICAL CHARACTERISTICS IN PATIENTS WITH ACUTE DECOMPENSATION OF HEART FAILURE. Nephrology Dialysis Transplantation, 2015, 30, iii450-iii450.	0.4	0
40	SP224PREVALENCE AND OUTCOMES OF CARDIORENAL INTERRELATIONS IN PATIENTS WITH ACUTE CARDIAC DISEASES. Nephrology Dialysis Transplantation, 2015, 30, iii451-iii452.	0.4	0
41	SP249PREVALENCE AND OUTCOMES IN COMMUNITY − ACQUIRED VERSUS HOSPITAL − ACQUIRED ACUTE KIDNEY INJURY IN PATIENTS WITH DECOMPENSATED HEART FAILURE. Nephrology Dialysis Transplantation, 2015, 30, iii461-iii461.	0.4	0
42	Pharmacokinetics of serelaxin in patients with hepatic impairment: a single dose, open label, parallel group study. British Journal of Clinical Pharmacology, 2015, 79, 937-945.	1.1	25
43	Chronic kidney disease: definition, classification, diagnostics, and treatment. Russian Journal of Cardiology, 2013, , 95-103.	0.4	3
44	Cardiovascular disease and renal function. Russian Journal of Cardiology, 2013, , 33-37.	0.4	3
45	Treating hypertension by rational use of diuretics: results of the Russian ARGUS-2 study. Current Medical Research and Opinion, 2009, 25, 2229-2237.	0.9	7
46	Association of medical staffing and outcomes in cardiovascular diseases. Russian Journal of Cardiology, 0, 25, 4236.	0.4	3
47	Efficiency of remote blood pressure monitoring in outpatients with hypertension: a pilot project in a city ambulatory care clinic. Russian Journal of Cardiology, 0, 25, 4149.	0.4	2